AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29547939 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty
Number of subjects: 354
Study 28913717 — intervention group
Group type: EXPERIMENTAL
Intervention: After Deployment, Adaptive Parenting Tools (ADAPT)
Number of subjects: 336
Study 28913717 — intervention group
Group type: COMPARATOR
Intervention: web and print resources-as-usual
Number of subjects: 336
Study 27100401 — intervention group
Group type: EXPERIMENTAL
Intervention: BpTRU device
Number of subjects: 62
Study 27100401 — intervention group
Group type: COMPARATOR
Intervention: WatchBP Office monitor
Number of subjects: 62
Study 25180056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 25180056 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg twice per day
Number of subjects: 160
Study 25180056 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 4 mg twice per day
Number of subjects: 160
Study 25180056 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 8 mg twice per day
Number of subjects: 160
Study 25180056 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 160
Study 21965229 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MFX)
Number of subjects: 1236
Study 21965229 — intervention group
Group type: COMPARATOR
Intervention: Nonstandardised antibiotic therapy (control)
Number of subjects: 1236
Study 21965229 — intervention group
Group type: EXPERIMENTAL
Intervention: β-lactam plus macrolide combination (BLM)
Number of subjects: 1236
Study 21965229 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MFX and BLM
Number of subjects: 1236
Study 19171612 — intervention group
Group type: EXPERIMENTAL
Intervention: Thimerosal exposure (62.5 microg)
Number of subjects: 1403
Study 19171612 — intervention group
Group type: EXPERIMENTAL
Intervention: Thimerosal exposure (137.5 microg)
Number of subjects: 1403
Study 19171612 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific thimerosal exposure mentioned)
Number of subjects: 1403
Study 17094530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (1 mg/kg)
Number of subjects: 0
Study 17094530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg)
Number of subjects: 0
Study 15274256 — intervention group
Group type: EXPERIMENTAL
Intervention: A-V Impulse System foot pump
Number of subjects: 200
Study 15274256 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 200
Study 11321236 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (80 microg or 250 microg) administered as a single injection with the first and second doses of hepatitis B vaccine
Number of subjects: 45
Study 11321236 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered at 0, 1, and 6 months
Number of subjects: 45
Study 11321236 — intervention group
Group type: EXPERIMENTAL
Intervention: Naïve T-helper cells (CD4+CD45RA+)
Number of subjects: 45
Study 11321236 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly who responded to HBV vs those who did not
Number of subjects: 45
Study 11321236 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and percent naive CD4 T cells
Number of subjects: 45
Study 9598220 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 36
Study 9598220 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 36
Study 7874712 — intervention group
Group type: EXPERIMENTAL
Intervention: 7F guiding catheters
Number of subjects: 115
Study 7874712 — intervention group
Group type: COMPARATOR
Intervention: 8F guiding catheters
Number of subjects: 115
Study 3137632 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methoxypsoralen (40 mg daily at 9 p.m.)
Number of subjects: 2
Study 3137632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31820602 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at 'three points of iliolumbar' combined with celecoxib (200 mg once a day for 3 days)
Number of subjects: 60
Study 31820602 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib alone (200 mg once a day for 3 days)
Number of subjects: 60
Study 28535791 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa (ERT)
Number of subjects: 32
Study 28535791 — intervention group
Group type: COMPARATOR
Intervention: Control (MorCAP untreated population)
Number of subjects: 32
Study 24992652 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation
Number of subjects: 44
Study 24992652 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 23436915 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment for 12 months
Number of subjects: 46
Study 23436915 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment for 24 months
Number of subjects: 46
Study 23436915 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 months
Number of subjects: 46
Study 21472815 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel
Number of subjects: 458
Study 18959591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydro-alcoholic solution of a phytocompound (20 gtt 30 min before meals for 2 weeks)
Number of subjects: 24
Study 14691428 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program at ventilatory threshold (VT) for 12 weeks
Number of subjects: 48
Study 14691428 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 48
Study 12043864 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFile Ni‐Ti.06 taper Series 29
Number of subjects: 10
Study 12043864 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFile GT rotary instrumentation techniques
Number of subjects: 10
Study 9821653 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional capsules in humans
Number of subjects: 0
Study 9821653 — intervention group
Group type: COMPARATOR
Intervention: Enteric coated tablets in humans
Number of subjects: 0
Study 9821653 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional capsules in dogs (pentagastrin pretreated)
Number of subjects: 0
Study 9821653 — intervention group
Group type: COMPARATOR
Intervention: Conventional capsules in dogs (saline pretreated)
Number of subjects: 0
Study 7666816 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol patch (50 micrograms daily) + levonorgestrel-releasing IUD (20 micrograms daily)
Number of subjects: 40
Study 7666816 — intervention group
Group type: COMPARATOR
Intervention: Oral therapy (2 mg of estradiol + 1 mg of noretisterone acetate daily)
Number of subjects: 40
Study 2757882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release acetazolamide (SRA) 500 mg once or twice daily
Number of subjects: 20
Study 2757882 — intervention group
Group type: COMPARATOR
Intervention: Conventional acetazolamide (CA) 500 mg once or twice daily
Number of subjects: 20
Study 2757882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release acetazolamide (SRA)
Number of subjects: 20
Study 2757882 — intervention group
Group type: COMPARATOR
Intervention: Conventional acetazolamide (CA)
Number of subjects: 20
Study 2757882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study 772394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesterolone (2 mg/kg orally for 6 months)
Number of subjects: 45
Study 772394 — intervention group
Group type: COMPARATOR
Intervention: Control (no androgens)
Number of subjects: 45
Study 30272630 — intervention group
Group type: EXPERIMENTAL
Intervention: Eviplera (TDF/FTC/RPV)
Number of subjects: 48
Study 30272630 — intervention group
Group type: COMPARATOR
Intervention: Atripla (TDF/FTC/EFV)
Number of subjects: 48
Study 29926644 — intervention group
Group type: EXPERIMENTAL
Intervention: Core strength training (n=8)
Number of subjects: 16
Study 24661263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and Cognitive-Behavioral Therapy (CBT)
Number of subjects: 196
Study 23257153 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic interview
Number of subjects: 521
Study 23257153 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice arm
Number of subjects: 521
Study 23257153 — intervention group
Group type: COMPARATOR
Intervention: Mail
Number of subjects: 521
Study 23257153 — intervention group
Group type: COMPARATOR
Intervention: Online
Number of subjects: 521
Study 21753776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactotripeptides (LTPs) at 3 mg per day for 6 weeks
Number of subjects: 52
Study 21753776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 19005687 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g ginger daily
Number of subjects: 162
Study 19005687 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g ginger daily
Number of subjects: 162
Study 19005687 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 162
Study 19005687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (both dosages)
Number of subjects: 162
Study 16849757 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenretinide at 2,475 mg/m2 per day for 7 days, repeated every 21 days.
Number of subjects: 54
Study 16849757 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenretinide at 3,300 mg/m2 per day (highest dose tested).
Number of subjects: 54
Study 16849757 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenretinide at 1,050 mg/m2.
Number of subjects: 54
Study 16849757 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenretinide at 1,860 mg/m2.
Number of subjects: 54
Study 16849757 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenretinide at 2,475 mg/m2.
Number of subjects: 54
Study 15619182 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management (166 participants)
Number of subjects: 331
Study 15619182 — intervention group
Group type: COMPARATOR
Intervention: Control group (165 participants)
Number of subjects: 331
Study 11735076 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention for battered women
Number of subjects: 33
Study 11735076 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study 9221964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg; 2g/kg and then 1 g/kg every three weeks)
Number of subjects: 20
Study 9221964 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha (IFN‐alpha; 3 MU/m2 subcutaneously three times weekly)
Number of subjects: 20
Study 8214548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline
Number of subjects: 50
Study 8214548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline and pethidine
Number of subjects: 50
Study 2886534 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose iv mezlocillin (5.0 g)
Number of subjects: 116
Study 2886534 — intervention group
Group type: COMPARATOR
Intervention: Three doses of iv cefuroxime plus metronidazole
Number of subjects: 116
Study 28616797 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol maleate fixed combination (BTFC)
Number of subjects: 50
Study 28616797 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol maleate fixed combination (LTFC)
Number of subjects: 50
Study 28616797 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost/timolol maleate fixed combination (TTFC)
Number of subjects: 50
Study 27061696 — intervention group
Group type: EXPERIMENTAL
Intervention: Return-to-work coordinator (RTWC) model of care
Number of subjects: 160
Study 27061696 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital standard care (Control)
Number of subjects: 160
Study 25008885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil [1 mg/(kg . d)] three times daily for 7‐10 days
Number of subjects: 50
Study 25008885 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 50
Study 21822734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluency performance
Number of subjects: 153
Study 21822734 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoding performance
Number of subjects: 153
Study 20569928 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper glycinate (2 mg copper/day) for 8 weeks
Number of subjects: 8
Study 20569928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 18164461 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method
Number of subjects: 0
Study 16351509 — intervention group
Group type: EXPERIMENTAL
Intervention: High-isoflavone soy diet (113-207 mg/day total isoflavones)
Number of subjects: 8
Study 16351509 — intervention group
Group type: COMPARATOR
Intervention: Low-isoflavone soy diet (<5 mg/day total isoflavones)
Number of subjects: 8
Study 12351534 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Org 31710
Number of subjects: 103
Study 12351534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 10196730 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-sex Stranger
Number of subjects: 0
Study 10196730 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-sex Best Friend
Number of subjects: 0
Study 10196730 — intervention group
Group type: COMPARATOR
Intervention: Alone
Number of subjects: 0
Study 8522409 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril 25 mg three times daily
Number of subjects: 70
Study 8522409 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol 200 mg twice daily
Number of subjects: 70
Study 8522409 — intervention group
Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 70
Study 1971872 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric delivery system (GDS) for iron supplementation, 50 mg daily
Number of subjects: 200
Study 1971872 — intervention group
Group type: COMPARATOR
Intervention: Conventional ferrous sulphate, 50 mg daily
Number of subjects: 200
Study 1971872 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric delivery system (GDS)
Number of subjects: 200
Study 1971872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 722473 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (tranquilizer condition)
Number of subjects: 0
Study 722473 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (amphetamine condition)
Number of subjects: 0
Study 722473 — intervention group
Group type: COMPARATOR
Intervention: Milk powder (placebo condition)
Number of subjects: 0
Study 31589645 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium iodide capsule (225 μg iodine) daily for 26 weeks
Number of subjects: 106
Study 31589645 — intervention group
Group type: COMPARATOR
Intervention: Iodized salt weekly for 26 weeks
Number of subjects: 106
Study 28925046 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous extract of Hibiscus sabdariffa (AEHS) 250 mg/kg and simvastatin 10 mg/kg
Number of subjects: 0
Study 28925046 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous extract of Hibiscus sabdariffa (AEHS) 500 mg/kg and simvastatin 20 mg/kg
Number of subjects: 0
Study 28925046 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous beverage of Hibiscus sabdariffa (ABHS) with single-dose simvastatin 40 mg
Number of subjects: 0
Study 28925046 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 0
Study 26281572 — intervention group
Group type: EXPERIMENTAL
Intervention: Fangfeng Tongsheng granule (3 g, twice a day for 14 days)
Number of subjects: 108
Study 26281572 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (simulated agent granules, 3 g, twice a day for 14 days)
Number of subjects: 108
Study 23858000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (intervention group)
Number of subjects: 4133
Study 23858000 — intervention group
Group type: EXPERIMENTAL
Intervention: Low body temperature group (<36 °C)
Number of subjects: 4133
Study 23858000 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 4133
Study 21681103 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.5 mg transdermal nicotine (TDN) patch
Number of subjects: 40
Study 21681103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (drug‐free bandage)
Number of subjects: 40
Study 19795771 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG group (nitroglycerin-induced hypotension)
Number of subjects: 40
Study 19795771 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 16396863 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.89 mg/kg over 10 days)
Number of subjects: 70
Study 16396863 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 70
Study 16396863 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 70
Study 15293485 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-orientated intervention (10 functional tasks for lower extremities, 3 times a week for 6 weeks)
Number of subjects: 91
Study 15293485 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (practice of upper extremity activities, 3 times a week for 6 weeks)
Number of subjects: 91
Study 15293485 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-orientated intervention
Number of subjects: 91
Study 11507005 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) following V(1) receptor blockade
Number of subjects: 0
Study 11507005 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 0
Study 10987239 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposuction (LS) combined with Controlled Compression Therapy (CCT)
Number of subjects: 0
Study 10987239 — intervention group
Group type: COMPARATOR
Intervention: Controlled Compression Therapy (CCT) alone
Number of subjects: 0
Study 10987239 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposuction (LS) + CCT
Number of subjects: 0
Study 8526697 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 2114
Study 8526697 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 2114
Study 1294490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-fortified milk formula
Number of subjects: 110
Study 6325044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg iv)
Number of subjects: 8
Study 6325044 — intervention group
Group type: COMPARATOR
Intervention: Control (no ketanserin)
Number of subjects: 8
Study 28828697 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT)
Number of subjects: 50
Study 28828697 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy (OT)
Number of subjects: 50
Study 25040706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 45
Study 25040706 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-partum women
Number of subjects: 45
Study 25040706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 25203881 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Residue Diet (LRD)
Number of subjects: 111
Study 25203881 — intervention group
Group type: COMPARATOR
Intervention: Clear Fluid (CF)
Number of subjects: 111
Study 22157367 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily
Number of subjects: 113
Study 22157367 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine 60 mg/m on days 1 and 8 every 3 weeks
Number of subjects: 113
Study 22157367 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (EGFR-mutated patients)
Number of subjects: 113
Study 22157367 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (EGFR-mutated patients)
Number of subjects: 113
Study 22157367 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (EGFR wild type)
Number of subjects: 113
Study 22157367 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (EGFR wild type)
Number of subjects: 113
Study 22157367 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib and Vinorelbine (EGFR-mutated vs wild type)
Number of subjects: 113
Study 19944151 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 10(8)TCID(50) IMVAMUNE dose
Number of subjects: 164
Study 19944151 — intervention group
Group type: EXPERIMENTAL
Intervention: All three IMVAMUNE doses
Number of subjects: 164
Study 18074075 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta products (Betaferon, Avonex, or Rebif)
Number of subjects: 94
Study 18074075 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 94
Study 16256861 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (10 microg/kg)
Number of subjects: 14
Study 16256861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16256861 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 14
Study 11904617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 50
Study 11904617 — intervention group
Group type: COMPARATOR
Intervention: Oral iron sulfate
Number of subjects: 50
Study 10208785 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 154
Study 10208785 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 154
Study 7603271 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation with social reinforcement (VR + SR)
Number of subjects: 24
Study 7603271 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation without social reinforcement (VR - SR)
Number of subjects: 24
Study 7603271 — intervention group
Group type: COMPARATOR
Intervention: General range of motion exercises with social reinforcement (ROM + SR)
Number of subjects: 24
Study 2152594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin 200 IU plus calcium 500 mg daily for 2 years
Number of subjects: 26
Study 2152594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin for 1 year
Number of subjects: 26
Study 2152594 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 age-matched women, no treatment)
Number of subjects: 26
Study 2152594 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of calcitonin treatment for 1 year
Number of subjects: 26
Study 31215777 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 31215777 — intervention group
Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 0